<DOC>
	<DOCNO>NCT00146705</DOCNO>
	<brief_summary>The aim study investigate long term outcome Peginterferon alpha-2b without addition lamivudine patient chronic hepatitis B</brief_summary>
	<brief_title>Long Term Follow-up Pegylated-Interferon Alpha-2b</brief_title>
	<detailed_description>Interferon alpha therapy generally accept agent treatment chronic HBV infection effective one third patient . Recently , HBV 99-01 study , pegylated interferon alpha-2b ( PEG-IFN ) show effective HBeAg-positive patient chronic hepatitis B . In study , 266 patient randomized receive PEG-IFN combination either lamivudine placebo 52 week . Thirty-six percent patient receive monotherapy thirty-five percent receive combination therapy lose serum HBeAg end 26 week post-treatment follow-up period difference treatment group ( P = 0.91 ) . More patient combination therapy initially seroconverted ( 44 % patient , compare 29 % monotherapy ; P = 0.01 ) end treatment relapse follow-up . Similar response pattern see response assess DNA suppression change ALT level . In contrast nucleoside analogue , lamivudine adefovir dipivoxil , virological biochemical response standard alpha-interferon show durable treatment discontinuation.In addition , standard alpha-interferon lead improved survival reduction hepatocellular carcinoma chronic hepatitis B patients.Pegylated interferon show effective HBeAg-positive chronic hepatitis B patient , durability response long-term outcome treatment yet establish .</detailed_description>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Patients chronic Hepatitis B participate HBV 9901 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>chronic HBV</keyword>
	<keyword>Peginterferon</keyword>
	<keyword>long term follow-up</keyword>
</DOC>